India Glycols Limited (NSE:INDIAGLYCO) filed the transcript of its Q1 FY27 earnings conference call on 20 August 2026, held on 14 August 2026. Management reported record EBITDA of Rs 170 crore, PAT growth of 32% year-on-year, and confirmed receipt of NCLT approval for a three-way business demerger.
Key Highlights
- Consolidated gross revenue rose 19% year-on-year in Q1 FY27, while net revenue reached Rs 1,130 crore, up 9% over the same period last year.
- EBITDA for the quarter stood at a record Rs 170 crore, up 13% year-on-year, with PAT growing 32% over Q1 FY26.
- Finance costs declined sharply to Rs 25 crore in Q1 FY27 from Rs 45 crore in Q1 FY26, reflecting significant debt reduction during the period.
- NCLT sanctioned the scheme of arrangement on 17 July 2026, paving the way for the Spirits, Bio-Fuel, and Bio Pharma businesses to transfer to dedicated resulting entities.
About the Company
India Glycols Limited (NSE:INDIAGLYCO), headquartered in Noida, Uttar Pradesh, is a specialty chemicals manufacturer that produces bio-based ethylene oxide, glycols, green solvents, and performance chemicals derived from renewable feedstocks. The company also operates potable spirits and ethanol businesses through its UP-based distilleries, and a nutraceuticals and active pharmaceutical ingredient business through its subsidiary Ennature Bio Pharma Limited. It is listed on both BSE (scrip code 500201) and NSE.
Announcement in Detail
Filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript covers the Q1 FY27 earnings call moderated by InCred Equities. CEO Rupark Sarswat reported that the Chemicals segment recorded revenue of Rs 362 crore, up 20.6% year-on-year, driven by bio-glycols, green solvents, and performance chemicals. The Spirits business posted revenue of Rs 361 crore, up 5.3%, with EBITDA growth of 14.2%, supported by premiumisation in Uttar Pradesh and Uttarakhand.
Ennature Bio Pharma reported its best-ever quarter, with revenue rising 65% year-on-year and EBITDA growing 188%, supported by new customer additions, nutraceutical product launches, and nicotine business expansion. The Bio-Fuel segment recorded revenue of Rs 323 crore, with EBIT rising 19% year-on-year to Rs 27 crore and an EBIT margin of 8.4%. Management also noted that EBITDA margin has improved steadily from 9.6% in FY22 to 15.5% in FY26, and the NCLT-approved demerger will create three separate listed entities, with the effective date yet to be communicated.
Impact on Investors
Investors will note that the filing shows finance costs nearly halved to Rs 25 crore in Q1 FY27 from Rs 45 crore in Q1 FY26, reflecting reduced debt levels and an improved debt-to-equity ratio, both of which the disclosed transcript attributes to active deleveraging. The filing also confirms that NCLT sanctioned the demerger scheme on 17 July 2026; however, the effective date for the transfer of the Spirits, Bio-Fuel, and Bio Pharma undertakings to dedicated resulting companies has not yet been communicated, which shareholders will observe introduces execution timing as a factor to monitor.
The disclosed terms of the demerger indicate that the remaining India Glycols Limited entity will retain the bio-based chemicals, specialty glycols, performance chemicals, and gases businesses. Shareholders of the current entity will need to review the scheme document for details on share entitlements in the resulting companies once the effective date is announced.
Sector / Market Context
India's specialty chemicals sector has seen sustained policy emphasis, with the government's Production Linked Incentive framework extended to certain chemical segments. The ethanol blending programme, monitored by the Ministry of Petroleum and Natural Gas, has driven demand for bio-ethanol, which directly relates to India Glycols' Bio-Fuel segment. The nutraceuticals market in India has also grown consistently, providing a supporting backdrop for the Ennature Bio Pharma business reported in this filing.